# A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas

> **NCT00704080** · PHASE1 · COMPLETED · sponsor: **Sanofi** · enrollment: 54 (actual)

## Conditions studied

- Mixed Gliomas
- Malignant Gliomas
- Glioblastoma Multiforme

## Interventions

- **DRUG:** XL765 (SAR245409)
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT00704080
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2012-02
- **Final completion:** 2013-02
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2013-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00704080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00704080, "A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00704080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*